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BACKGROUND: Cardiac remodeling, after a myocardial insult, often 
causes progression to heart failure. The relationship between alterations in 
left ventricular blood flow, including kinetic energy (KE), and remodeling 
is uncertain. We hypothesized that increasing derangements in left 
ventricular blood flow would relate to (1) conventional cardiac remodeling 
markers, (2) increased levels of biochemical remodeling markers, (3) 
altered cardiac energetics, and (4) worsening patient symptoms and 
functional capacity.
METHODS: Thirty-four dilated cardiomyopathy patients, 30 ischemic 
cardiomyopathy (IHD) patients, and 36 controls underwent magnetic 
resonance including 4-dimensional flow, BNP (brain-type natriuretic 
peptide) measurement, functional capacity assessment (6-minute walk 
test), and symptom quantification. A subgroup of dilated cardiomyopathy 
and control subjects underwent cardiac energetic assessment. Left 
ventricular flow was separated into 4 components: direct flow, retained 
inflow, delayed ejection flow, and residual volume. Average KE 
throughout the cardiac cycle was calculated.
RESULTS: Patients had reduced direct flow proportion and direct-flow 
average KE compared with controls (P<0.0001). The residual volume 
proportion and residual volume average KE were increased in patients 
(P<0.0001). Importantly, in a multiple linear regression model to predict 
the patient’s 6-minute walk test, the independent predictors were age 
(β=−0.3015; P=0.019) and direct-flow average KE (β=0.280, P=0.035; 
R2 model, 0.466, P=0.002). In contrast, neither ejection fraction nor left 
ventricular volumes were independently predictive.
CONCLUSIONS: This study demonstrates an independent predictive 
relationship between the direct-flow average KE and a prognostic 
measure of functional capacity. Intracardiac 4-dimensional flow 
parameters are novel biomarkers in heart failure and may provide additive 
value in monitoring new therapies and predicting prognosis.
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Heart failure (HF) is a global health burden with significant morbidity and mortality.1 It is a com-plex multifactorial syndrome that is initiated by a 
myocardial insult, which activates cardiac remodeling—
a process encompassing numerous transcriptional, cel-
lular, and architectural changes within both cardiac 
myocytes and surrounding extracellular structures.2 The 
ability of the heart to remodel in response to stimuli 
is important for cardiovascular adaptation in altered 
physiological conditions, such as pregnancy.3 However, 
in pathological remodeling, this initially beneficial plas-
ticity response becomes maladaptive with a propensity 
toward hypertrophy, ventricular dilatation, systolic dys-
function, and electrophysiological changes resulting in 
ventricular arrhythmias and HF.2,3
Fluid dynamic studies indicate that the morphologi-
cal structure of a compliant vessel is inextricably linked 
to the flow within it.4 Hence, as ventricular flow is 
altered in the early stages of remodeling,5 it is probable 
that the flow itself can influence disease progression.4 
Insights into and quantification of left ventricular (LV) 
blood flow and kinetic energy (KE) are now afforded 
by 3-dimensional, time-resolved magnetic resonance 
imaging (4-dimensional [4D] flow).6 Previous studies 
have demonstrated altered LV flow patterns in seem-
ingly compensated dilated cardiomyopathy (DCM) 
patients,5 as well as higher KE in severe HF.7 However, 
no studies have found relationships between intracar-
diac blood flow parameters and the functional ability of 
patients with HF.
BNP (brain-type natriuretic peptide) produced 
by cardiac myocytes in response to volume expan-
sion and pressure overload is a powerful prognostic 
HF marker.8 Functional capacity in HF, as represented 
by the distance covered during a 6-minute walk test 
(6MWT), is also a predictor of mortality and morbid-
ity,9 as is the presence of symptoms as assessed with 
a standardized questionnaire (Minnesota Heart Failure 
Questionnaire).10
Cardiac phosphorus magnetic resonance spectros-
copy allows noninvasive measurement of the phospho-
creatine-to-ATP concentration ratio (PCr/ATP), which is 
a sensitive marker of myocardial energetics. Impaired 
myocardial energetics (decreased PCr/ATP) in DCM 
patients are predictive of mortality.11 However, the rela-
tionship between derangements in myocardial energet-
ics and LV blood flow is unknown.
Much remains to be understood about cardiac 
remodeling2; the aim of this study was to investigate 
the relationship between ventricular morphology, func-
tion, and blood flow during cardiac remodeling. In this 
study, patients were included with 2 of the commonest 
causes of HF—ischemic heart disease (IHD) and DCM.1 
We hypothesized that increasing derangements in LV 
blood flow would relate to (1) conventional cardiac 
remodeling markers, (2) increased levels of biochemi-
cal remodeling markers, (3) altered cardiac energetics, 
and (4) worsening patient symptoms and functional 
capacity.
Further, we hypothesized these changes to be 
independent of the cause of the myocardial damage, 
instead reflecting the self-propagating nature of car-
diac remodeling and that 4D flow parameters would 
be more powerful predictors of the functional conse-
quences of cardiac remodeling than conventional imag-
ing parameters.
METHODS
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure because of a lack 
of ethical approval to share datasets beyond the host institu-
tion’s research team.
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CLINICAL PERSPECTIVE
Cardiac magnetic resonance imaging plays a cen-
tral role in the diagnosis and prognostication of 
patients with heart failure. In this current study, 
we investigated the clinical utility of 4-dimen-
sional flow imaging compared with conventional 
imaging and clinical prognostic markers. The left 
ventricular flow was divided into 4 functional 
components and the kinetic energy of each 
flow component calculated throughout the car-
diac cycle. We found that in patients with either 
ischemic or dilated cardiomyopathy, there was a 
decrease in the volume and kinetic energy of the 
direct flow component compared with healthy 
controls. The degree of derangement in the direct 
flow parameters worsened as the left ventricular 
ejection fraction declined. The direct-flow aver-
age kinetic energy correlated negatively with the 
conventional remodeling parameters of left ven-
tricular end-diastolic and end-systolic volumes, 
patient symptoms (as measured by a validated 
questionnaire), and B-type natriuretic peptide lev-
els (P<0.0001). This is the first study that found in 
a multiple linear regression model that the direct-
flow average kinetic energy was predictive of the 
patient’s functional capacity, as measured by the 
distance covered during a 6-minute walk test. 
Conventional imaging parameters including left 
ventricular ejection fraction were not predictive 
of the patient’s functional capacity. These results 
suggest that intracardiac 4-dimensional flow 
parameters are novel biomarkers in heart failure 
and warrant further investigation in longitudinal 
studies as a marker of prognosis in patients with 
heart failure.
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Study Population
This study was approved by the National Research Ethics 
Committee. Each participant gave written informed consent. 
Hundred participants were recruited; 34 DCM, 30 ischemic 
cardiomyopathy (IHD), and 36 healthy controls. See Methods 
in the Data Supplement for inclusion/exclusion criteria.
Cardiac Magnetic Resonance Protocol
Imaging was performed at 3.0 T (Trio; Siemens Healthcare, 
Erlangen, Germany) using a 32-channel cardiac coil. Standard 
cine and strain imaging were performed (see Methods in the 
Data Supplement).12,13
4D flow acquisitions were free breathing, using a ret-
rospectively ECG triggered, respiratory navigator gated, 
3-dimensional, 3-directional, time-resolved phase-contrast 
magnetic resonance imaging sequence with a 52-ms mea-
surement temporal resolution and 3×3×3 mm3 voxel size, 
with velocity encoding 100 cm/s.
CMR Data Analysis
LV volumes were analyzed using cmr42 (Circle Cardiovascular 
Imaging, Inc, Calgary, Canada) as described previously.12 LV 
sphericity index was calculated by division of the horizontal 
long-axis length by the maximum diameter at end diastole.
Tagged images were analyzed for midventricular peak 
systolic circumferential strain and diastolic strain rate using 
Cardiac Image Modeller software (CIMTag2D v7; Auckland, 
New Zealand).13
4D Flow Data Analysis
LV blood flow was analyzed using methodology described 
by Eriksson et al,14 consisting of endocardial segmentation 
at end diastole and end systole, with pathline generation 
from each segmented voxel. The position of pathlines at end 
systole divides them into 4 functional flow components as 
described previously5,14: (1) direct flow: blood that enters and 
exits the LV in the analyzed cardiac cycle; (2) retained inflow: 
enters the LV but does not exit during the analyzed cycle; (3) 
delayed ejection flow: starts within the LV and exits during the 
analyzed cycle; and (4) residual volume: blood that remains in 
the LV for at least 2 cardiac cycles. Each component volume 
was calculated as a proportion of the total end-diastolic vol-
ume. LV segmentation was performed in Segment (version 
1.9R2842) and flow visualization in EnSight (CEI, Inc, NC).
Each component’s KE was calculated throughout the 
cardiac cycle using KE=½·ρ
blood·Vpathline·v2pathline, where ρblood 
is blood density; Vpathline, the blood volume represented by 1 
pathline, and Vpathline, the pathline velocity. The KE for each 
component is the sum of KE for each of its pathlines. Two dif-
ferent measurements of KE are reported within this study: (1) 
KE at end diastole and (2) average KE. (1) KE at end diastole: 
as in previous studies, KE for each component was recorded 
at end diastole, as these reflect the preservation of the inflow-
ing KE before the rapid systolic ejection of blood.5 (2) Average 
KE: this was calculated for each flow component to assess 
whether the inclusion of all time frames provided additional 
information. The average KE was calculated by adding the KE 
values for the entire flow component’s pathlines throughout 
the cardiac cycle. This summed value was then divided by 30 
to reflect the average KE for that flow component per time 
frame. Using the average KE values, the proportion of the 
direct-flow average KE was derived by dividing the direct-flow 
average KE by the total average KE for all components. The 
same calculation was performed with the residual volume 
average KE to derive the proportion of the residual volume 
average KE. Both measures of KE (KE at end diastole and 
average KE) were additionally normalized to the end-diastolic 
volume.
Phosphorus Magnetic Resonance Spectroscopy
Twenty-five patients with DCM and 10 controls under-
went phosphorus magnetic resonance spectroscopy at 7T 
(Magnetom; Siemens, Germany), as previously described by 
our group in controls and patients (see Methods in the Data 
Supplement).15,16 IHD patients were not included in this sub-
study because of the regionality of the LV dysfunction.
Statistical Analysis
Statistics were analyzed using SPSS 22 (Chicago, IL). Normality 
testing utilized the D’Agostino and Pearson omnibus normal-
ity test; data are presented as mean±SDs, unless otherwise 
specified. One-way ANOVA with post hoc Tukey or Kruskal-
Wallis H with post hoc Dunn multiple-comparison tests 
were performed as appropriate. Correlation was assessed 
using the Pearson or Spearman method. P <0.05 was con-
sidered significant. Multiple linear regression models were 
created, using stepwise entry and the dependent variable 
as the patient 6MWT result. Variables with P <0.05 that had 
the strongest relationship with 6MWT were included in the 
model. Linear model fit was assessed by visually checking the 
linearity assumption. Residuals were normally distributed. 
Standardized (β) values are reported.
RESULTS
Participant Characteristics
Demographic and clinical data are shown in Table  1. 
There were no significant differences in age or heart 
rate between groups. Blood pressure tended to be low-
er in the patients, likely reflecting HF and pharmaco-
therapy (Table I in the Data Supplement). As expected, 
patients with IHD and DCM patients had higher BNP 
levels compared with controls (P<0.0001). Mean dis-
tance walked was 20% less in DCM and 25% less in 
patients with IHD compared with controls (P<0.0001).
Myocardial Structure and Function
Results for LV volumes and function are summarized in 
Table 2. The 2 patient groups, as expected, had signifi-
cantly increased LV volumes and decreased systolic func-
tion compared with controls (P<0.0001). Both patient 
groups had a more spherical ventricle with impaired 
systolic strain compared with controls (P<0.0001). 
There were no significant differences between the 
patient groups.
AQ9
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Changes in Flow Components
Flow visualizations are shown in Figure 1 and Movies in 
the Data Supplement. The changes in proportion of the 
flow components, compared with controls, were simi-
lar between the DCM and IHD groups Figure 2. DCM 
was associated with a 71% and IHD a 63% decrease 
in the direct flow component proportion compared with 
controls (P<0.0001). This decrease in direct flow corre-
sponded to a similar increase in the residual volume com-
ponent in both DCM (63% increase) and IHD patients 
(70% increase) compared with controls (P<0.0001).
Changes in KE Profiles
KE values for all 4 flow components differed significant-
ly for the DCM and IHD groups compared with controls 
but not between the patient groups Figure 3. In con-
trols, the efficient direct flow component possessed the 
greatest KE; in patients with DCM and IHD, this was 
decreased (DCM average KE, 60% decrease, and IHD, 
56% decrease, versus controls; P<0.0001; Figure 3B), 
and the KE of the other 3 flow components increased 
compared with controls. These KE changes were seen 
for both KE at end diastole and the average KE, but the 
magnitude of change differed depending on which KE 
measure was assessed (Figure 3A and 3B).
The proportion of the direct-flow average KE com-
pared with the total average KE of all flow compo-
nents was the highest for the control group (64±8%), 
compared with DCM of 23±14% and IHD of 29±19% 
(P<0.0001). The residual volume average KE proportion 
was significantly higher in the 2 patient groups (DCM, 
17±11%; IHD, 15±12%) compared with controls 
(4±2%; P<0.0001).
The derangement in the proportion and KE values 
of the flow components progressed as the LV ejection 
F1
F2
F3
Table 1. Baseline Characteristics
Controls (n=36) DCM (n=34) IHD (n=30)
P Value, DCM vs 
Controls
P Value, IHD vs 
Controls
Demographics
  Age, y 57±12 57±14 63±12 1.0 0.125
  Men, n (%) 25 (70) 22 (65) 28 (93) 0.89 0.062
  BMI, kg/m2 25±4 28±4 28±4 0.04 0.007
  Systolic BP, mm Hg 134±20 128±18 120±15 0.375 0.007
  Diastolic BP, mm Hg 78±10 72±12 69±9 0.044 0.003
  Heart rate, bpm 64±14 65±14 65±14 0.988 0.967
Prognostic markers
  BNP, pmol/L 7±5 51±105 77±108 <0.0001 <0.0001
  6MWT, m 624±77 500±84 470±101 <0.0001 <0.0001
  MHFQ … 18±19 22±22 … …
Values are mean±SDs or percentages. 6MWT indicates 6-min walk test; BMI, body mass index; BNP, brain natriuretic 
peptide; BP, blood pressure; DCM, dilated cardiomyopathy; IHD, ischemic heart disease; and MHFQ, Minnesota Heart Failure 
Questionnaire.
Table 2. CMR Results in Controls, IHD Patients, and DCM Patients
Variable Controls (n=36) DCM (n=34) IHD (n=30)
P Value, DCM vs 
Controls
P Value, IHD 
vs Controls
LV end-diastolic volume, mL 159±31 273±118 231±68 <0.0001 <0.0001
LV end-diastolic volume–indexed BSA, mL/m2 82±14 135±52 116±33 <0.0001 <0.0001
LV end-systolic volume, mL 53±13 182±108 146±65 <0.0001 <0.0001
LV stroke volume, mL 106±20 90±25 85±22 0.012 0.001
LVEF, % 67±4 36±11 39±12 <0.0001 <0.0001
Cardiac output, L/min 6.7 5.6 5.2 0.003 <0.0001
LV mass, g 113±35 137±46 137±30 0.010 0.081
LV mass index, g/m2 58±15 69±20 68±13 <0.0001 0.038
LV sphericity index 1.7±0.2 1.4±0.2 1.4±0.2 <0.0001 <0.0001
Midventricular circumferential systolic strain, % (negative) 19±3 10±4 12±4 <0.0001 <0.0001
Midventricular diastolic strain rate, s−1 83±19 48±21 53±18 <0.0001 <0.0001
Values are mean±SDs or percentages. BSA indicates body surface area; DCM, dilated cardiomyopathy; IHD, ischemic heart disease; LV, left ventricle; 
and LVEF, left ventricular ejection fraction.
AQ10
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fraction (LVEF) decreased, as illustrated in Figure 4. The 
proportion of the direct flow decreased in line with 
the ejection fraction. However, the decrease in direct-
flow KE occurred only with the development of more 
advanced HF, with an ejection fraction of ≤44% (Fig-
ure 4B and 4C). The proportion and KE of the residual 
volume component increased steadily as LV impairment 
worsened (Figure  4J through 4L). As with the direct 
flow, the change in the KE of the residual volume, in 
this case an increase, occurred with more advanced HF, 
with ejection fraction of ≤44%.
Association of Novel 4D Flow Parameters 
With Classical Remodeling and 
Prognostic Markers
The correlation coefficients for the direct flow and 
residual volume KE across all participants are shown in 
F4
Figure 1. Representative diastolic left ventricular (LV) visualizations in a control (direct flow, 35%; residual volume, 29%), dilated cardiomyopathy 
(DCM; direct flow, 10%; residual volume, 55%), and ischemic cardiomyopathy (IHD) patient with an anteroapical infarct (direct flow, 8%; residual 
volume, 56%).  
Despite similar proportions of residual volume between the IHD and DCM patients, the distribution differs, with a global distribution in the DCM patient and a 
more localized distribution in the IHD patient, corresponding to the area of infarction. Direct flow, green; retained inflow, yellow; delayed ejection flow, blue; and 
residual volume, red. Ao indicates aorta; and LA, left atrium.
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Table 3. Direct-flow KE correlated negatively with the 
conventional remodeling parameters of LV end-diastol-
ic volume, LV end-systolic volume, and positively with 
LVEF (P<0.0001). Residual volume KE correlated nega-
tively with the LVEF and positively with the LV end-dia-
stolic volume and LV end-systolic volume (P<0.0001). 
Both the direct flow and residual volume KE correlated, 
but in opposite directions, with the patients’ symptoms 
(Minnesota Heart Failure Questionnaire), their func-
tional capacity (6MWT), and biochemical evidence of 
cardiac remodeling (BNP).
KE values for direct flow and residual volume accord-
ing to distance covered during the 6MWT are shown 
in Table 4. The direct-flow average KE was found to be 
different depending on the distance walked (P=0.008).
To assess whether remodeling parameters were pre-
dictive of the patient’s functional capacity, as represent-
ed by the 6MWT, a multiple linear regression model was 
created. The independent variables entered into the 
model were age, height, LVEF, BNP, direct-flow average 
KE, and peak systolic circumferential strain. Importantly, 
the independent predictors of the 6MWT were found 
to be age (β=−0.315; P=0.019) and direct-flow average 
KE (β=0.280; P=0.035; overall R2 of the model, 0.466; 
Table II in the Data Supplement). To avoid colinearity of 
predictors, the other prognostic remodeling parameters 
of end-systolic volume and end-diastolic volume were 
substituted into the model above instead of LVEF, but in 
these subsequent models, age and direct-flow average 
KE remained the only independent predictors. Thus, 
direct-flow average KE was, but traditional remodeling 
parameters were not, independent predictor of func-
tional capacity in these HF patients.
Associations Between Myocardial 
Energetics and 4D Flow Parameters in DCM
In keeping with previous studies,11 we found a reduced 
PCr/ATP ratio in DCM compared with controls (PCr/ATP, 
1.54±0.39 versus 1.95±0.25; P=0.005; Figure  5A). The 
PCr/ATP ratio correlated with the classical remodeling 
parameters of LVEF (r=0.527; P=0.01; 95% CI, 0.11–0.72), 
LV end-diastolic volume (r=−0.587; P=0.0002; 95% CI, 
−0.79 to −0.15), and LVESV (r=−0.601; P=0.0001; 95% 
CI, −0.80 to −0.21), as well as the peak systolic circum-
ferential strain (r=0.507; P=0.003; 95% CI, 0.19–0.74). 
In addition, the PCr/ATP ratio correlated with 4D flow 
parameters (Figure 5B through 5F) including the propor-
tion of the direct-flow average KE (r=0.45; P=0.007; 95% 
CI, 0.05–0.73) and proportion of the residual volume 
average KE (r=−0.41; P=0.014; 95% CI, −0.67 to −0.03).
DISCUSSION
In this work, the relationships between ventricular mor-
phology, prognostic markers, and novel 4D flow param-
eters during cardiac remodeling because of dilated and 
ischemic cardiomyopathy were assessed using CMR. We 
demonstrate that the average KE of the direct flow and 
residual volume correlate with conventional remodeling 
parameters and prognostic markers, suggesting a role as 
novel cardiac remodeling imaging biomarkers. Important-
ly, we show that the direct-flow average KE is predictive of 
the patient’s functional capacity, whereas the LVEF and LV 
volumes were not. We demonstrate that changes in flow 
components and KE, as seen previously in DCM patients,5 
are similar in ischemic cardiomyopathy, despite a different 
myocardial insult cause. Finally, we demonstrate that in 
DCM, there is a relationship between the impaired myo-
cardial energetics and the KE of the LV flow components.
Consequences of Alterations in LV Flow 
Components and KE
In health, most inflow volume and hence KE of blood 
from the left atrium (direct flow and retained inflow) 
T3
T4
F5
AQ14
Figure 2. Flow components by percentage of the end-diastolic volume 
(EDV) for (A) control, (B) dilated cardiomyopathy (DCM), and (C) isch-
emic cardiomyopathy (IHD).  
Data are mean±SD. All comparisons between DCM and IHD patients were 
nonsignificant. ****P<0.0001, **P<0.01, *P<0.05 compared with corre-
sponding component in controls.
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is because of direct flow, which preserves its KE as 
it transits the LV.17 We identified that in DCM and 
IHD, the majority of the inflowing volume and KE is 
because of the retained inflow component. Hence, 
instead of immediate ejection as part of the direct 
flow, the KE possessed by the retained inflow resides 
within the LV for at least 1 cardiac cycle before ejec-
tion. The KE of this blood has several possible fates 
in the receiving ventricle, it may (1) be transferred as 
KE to the blood already residing in the LV (delayed 
ejection flow and residual volume), (2) be converted 
into potential energy that is either stored within the 
elastic recoil of the myocardium or causes an eleva-
tion in ventricular pressure, or (3) be dissipated in 
the form of friction/heat.5 With any of these fates, 
energy is dissipated or converted into less efficient 
configurations within the ventricle, and the KE of the 
LV residing components is increased compared with 
the situation in health.
Many processes that occur as a consequence of car-
diac remodeling have initial advantageous effects that 
become deleterious over time; it may be that increasing 
the residual volume in ventricular dysfunction initially 
confers an advantage such as acting as a buffer to redis-
tribute KE, so as to reduce transfer of KE to potential 
energy that would result in elevated ventricular pres-
sure. However, when either the myocardium remodels 
becoming less compliant or the LV pressure exceeds a 
certain level, the conversion of KE to potential energy 
declines and may explain why we see the sharp rise in 
the residual volume average KE once end-stage remod-
eling is reached, suggesting failure of any compensato-
ry mechanisms. The KE of the residual volume may also 
have a role in prevention of blood stasis and thrombus 
formation, as suggested by a Doppler study that found 
lower apical blood velocities in patients with thrombus 
compared with those without.18
Relation to Earlier Studies
Previous work by Eriksson et al5 and Kanski et al7 found 
that patients with HF have higher KE values compared 
with controls. Eriksson et al5 studied patients with clini-
cally compensated DCM and found similar but less pro-
AQ15
Figure 3. Kinetic energy (KE) profiles.  
A, KE at end diastole; (B) KE at end diastole normalized to end-diastolic volume (EDV); (C) average KE throughout the cardiac cycle; and (D) average KE normalized 
to EDV. Bars show minimum and maximum values. All comparisons between dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (IHD) patients were 
nonsignificant (NS). ED indicates end diastole. ****P<0.0001, ***P<0.001 compared with corresponding component value in controls.
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nounced alterations in the flow component volumes 
with reduced direct flow and increases in the other 
flow components. This study looked at KE values at 
end diastole and found, as we did, an increase in KE of 
the retained inflow, delayed ejection flow, and residual 
volume. Unlike our results, they did not see a difference 
in the KE of the direct flow between the DCM patients 
and controls, but their patients had better systolic func-
tion (mean LVEF, 42%, and preserved stroke volume 
versus our values of LVEF, 36% DCM and 39% IHD, 
with reduced stroke volume), which may explain this 
difference.
Kanski et al7 evaluated the average KE of the total 
ventricular blood volume in patients with HF. They found 
no difference in diastolic average KE between patients 
and controls but higher average systolic KE. They did 
not find any relationship between the patients’ symp-
toms or functional capacity and the total KE. This lack 
of association is likely because of consideration of the 
blood volume as a whole rather than as flow compo-
Figure 4. Differences in flow component percentage, kinetic energy at end diastole (ED), and average kinetic energy according to left ventricular 
ejection fraction (LVEF).  
LVEF, >55% (n=4); ejection fraction (EF), 45% to 54% (n=11); EF, 36% to 44% (n=21); EF, ≤35% (n=28). A, D, G, and J, Bars show mean value, and error bars in-
dicate SD. Other bars show minimum and maximum values. EDV indicates end-diastolic volume; and KE, kinetic energy. *P<0.05 compared with controls; §P<0.05 
LVEF ≤35% compared with 45% to 54%; ∂P<0.05 LVEF ≤35% compared with ≥55%; #P<0.05 LVEF 36% to 44% compared with 45% to 54%.
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nents as in our study. Interestingly, in Fontan patients, 
Sjöberg et al19 found that the peak diastolic, but not sys-
tolic, KE indexed to stroke volume was lower in Fontan 
patients than controls. These varying results depending 
on the cause of myocardial injury suggest that there is 
still much to be understood about intracardiac KE.
Potential Clinical Utility of Intracardiac 
KE Assessment
To our knowledge, our work is the first to demonstrate 
that the KE of both the direct flow and the residual 
volume flow components correlated with conventional, 
established prognostic markers for HF, including BNP 
levels, HF symptoms, and functional capacity. These 
results support a clinical utility for KE evaluation in the 
management and follow-up of patients with HF. Cur-
rent volumetric-based cardiac imaging techniques have 
limited ability to provide prognostic information for this 
patient cohort. In the future, it is hoped that by incor-
porating more advanced imaging techniques, such as 
4D flow KE assessments, the predictive ability of cardiac 
imaging to provide prognostication in patients with HF 
can be further refined and aid appropriate targeting of 
new therapies to those patients most at risk of compli-
cations. However, before generalized use of 4D flow for 
clinical assessments occurs, our results require further 
validation in a larger multicenter study to fully estab-
lish the reproducibility between centers and the clinical 
potential of this technique.
Candidate Pathophysiological 
Mechanisms for Transduction of 
Blood Flow Abnormalities to Cardiac 
Remodeling
Blood flow within the LV is subject to the laws of 
mechanics including that of Laplace; ventricular wall 
stress is proportional to ventricular pressure and cavity 
radius and inversely proportional to the wall thickness.2 
If KE conversion to potential energy causes increased LV 
pressure, especially diastolic pressure, this would result 
Table 3. Correlations Between Ventricular Remodeling Parameters, Prognostic Markers, KE at Both End Diastole and Average KE for Direct Flow 
and Residual Volume
Variable
Direct-Flow KE at ED Direct-Flow Average KE Residual Volume KE at ED Residual Volume Average KE
r P Value (95% CI) r P Value (95% CI) r P Value (95% CI) r P Value (95% CI)
LV EDV −0.35 <0.0001  
(−0.50 to −0.14)
−0.41 <0.0001  
(−0.52 to −0.18)
0.78 <0.0001  
(0.64 to 0.85)
0.88 <0.0001  
(0.79 to 0.92)
LV ESV −0.55 <0.0001  
(−0.65 to −0.37)
−0.64 <0.0001  
(−0.70 to −0.46)
0.89 <0.0001  
(0.81 to 0.91)
0.93 <0.0001  
(0.86 to 0.95)
LV EF 0.66 <0.0001  
(0.50 to 0.75)
0.79 <0.0001  
(0.65 to 0.84)
−0.88 <0.0001  
(−0.90 to −0.79)
−0.86 <0.0001  
(−0.90 to −0.76)
MHFQ −0.56 <0.0001  
(−0.70 to −0.40)
−0.63 <0.0001  
(−0.73 to −0.50)
0.60 <0.0001  
(0.43 to 0.73)
0.58 <0.0001  
(0.42 to 0.71)
6MWT 0.46 <0.0001  
(0.28 to 0.62)
0.60 <0.0001  
(0.45 to 0.72)
−0.50 <0.0001  
(−0.63 to −0.33)
−0.43 <0.0001  
(−0.57 to −0.23)
Circumferential 
systolic strain
−0.56 <0.0001  
(−0.69 to −0.39)
−0.73 <0.0001  
(−0.80 to −0.59)
0.78 <0.0001  
(0.69 to 0.86)
0.77 <0.0001  
(0.66 to 0.84)
BNP −0.45 <0.0001  
(−0.57 to −0.20)
−0.58 <0.0001  
(−0.64 to −0.34)
0.53 <0.0001  
(0.29 to 0.62)
0.51 <0.0001  
(0.22 to 0.60)
Correlations are performed with Pearson or Spearman correlation as appropriate. 6MWT indicates 6-min walk test; BNP, brain-type natriuretic peptide; ED, 
end diastole; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; KE, kinetic energy; LV, left ventricle; and MHFQ, Minnesota Heart Failure 
Questionnaire.
Table 4. Results for Direct Flow Percentage and KE Values and Residual Volume Percentage and KE Values 
According to Distance Covered During 6MWT
6MWT, <450 m 
(n=17)
6MWT, 451–550  
m (n=31)
6MWT, >551  
m (n=16) P Value
Direct flow (percentage of EDV) 9.8±4.4 13.6±8.7 13.7±8.9 0.264
Direct-flow KE at ED, mJ 0.17±0.12 0.24±0.25 0.24±0.15 0.456
Direct flow average KE, mJ 2.41±1.32 3.93±2.80 5.71±3.95 0.008
Residual volume (percentage of EDV) 53.7±9.3 49.0±11.6 48.0±9.4 0.261
Residual volume KE at ED, mJ 0.40±0.29 0.35±0.41 0.44±0.38 0.745
Residual volume average KE, mJ 2.23±1.51 2.23±2.43 2.27±1.59 0.989
Values are mean±SDs. 6MWT indicates 6-min walk test; ED, end diastole; EDV, end-diastolic volume; and KE, 
kinetic energy.
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in increased ventricular wall stress/stretch, which may 
be important in the activation of cardiac remodeling 
pathways.3 Translating stretch stimuli to downstream 
signaling requires numerous complex pathways includ-
ing transient receptor potential channels, integrins, as 
well as the sarcomere-spanning protein titin.20 Once 
cardiac myocytes have sensed mechanical stretch, they 
convert this into intracellular growth signals and chang-
es in gene expression.21
A common early feature of cardiac remodeling is 
an increase in wall thickness to reduce wall stress and 
decrease oxygen demand; however, when the wall 
stress is sustained, the myocardium slowly transitions 
to a state of decompensation and subsequent HF. Part 
of the cardiac myocyte response to mechanical stress 
is to reactivate a pattern of gene expression similar to 
that required during fetal growth, which includes BNP.2 
Reexpression of fetal genes during remodeling provides 
further evidence for the potential influence of cardiac 
blood flow on morphological changes; in fetal cardiac 
development, mechanical signals from blood flow, via 
induction of gene expression, promote ventricular cell 
enlargement and contractility.22
Additional support for the importance of intracar-
diac blood flow on myocardial cellular processes is 
provided by tissue samples obtained before and after 
implantation of a LV assist device in patients with 
HF, which demonstrated reverse remodeling chang-
Figure 5. Myocardial energetics results and correlations in dilated cardiomyopathy (DCM) patients.  
A, Phosphocreatine-to-ATP concentration ratio (PCr/ATP) in controls compared with DCM. Correlations between PCr/ATP ratio and (B) proportion of direct-flow 
average kinetic energy (KE); (C) proportion of residual volume average KE; (D) residual volume average KE; (E) retained inflow average KE; and (F) delayed ejection 
flow average KE.
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es including regression of cell thickening/elongation 
and reversion of gene expression controlling calcium 
cycling.23
Myocardial Energetics and 
Intraventricular Blood Flow
Myocardial energetics were associated with the pro-
portion of the direct-flow average KE. This suggests 
that, as well as the direct-flow KE, the KE of the com-
ponents that remain within the LV for at least 1 cycle 
are also important. One explanation for this may relate 
to altered cardiac substrate metabolism as a conse-
quence of reactivation of the fetal gene program by 
abnormal LV stretch (caused by the KE of the LV resid-
ing components). Hence, it may be that the activation 
of this gene program shifts myocardial metabolism 
from dominant fat to dominant glucose metabolism.24 
Metabolizing glucose requires less oxygen per unit 
of ATP generated than metabolizing fat, but a mole 
of glucose has significantly lower chemical potential 
energy than a mole of fat. This metabolic shift might 
impair ATP generation in advanced HF.25 In support of 
this, mechanical unloading of failing hearts with LV 
assist devices is associated with at least partial normal-
ization of cardiac metabolism.26
Study Limitations
4D flow acquisitions were at rest, and although asso-
ciations were found with the patients’ functional 
capacity, these relationships and understanding of 
blood flow changes in HF may elucidate additional 
mechanisms if assessed during pharmacological or 
exercise stress.
An alternative selection method for the variables to 
include in the multiple linear regression model could 
have been used, such as setting the significance level 
higher (eg, P<0.2) or using index criteria. However, 
these methods were not used because this would 
have resulted in more eligible variables, which with 
the limited sample size available may have resulted 
in overfitting of the data. However, we acknowl-
edge that the selection method used means other 
relevant variables may have been excluded from the 
current model, which should be investigated further 
in future studies with larger sample sizes. In addition, 
the results are primarily unadjusted, and the sample 
size has limited ability to fully adjust for covariates. 
The lack of significance of covariates in the analysis 
cannot exclude these as parameters of importance 
and may instead be because of a small effect that 
the limited study size sample was unable to detect. 
This will require future larger sample size studies to 
investigate further.
Potential selection bias based on recruitment 
from patients under tertiary-level care, as well as for 
controls who volunteered for the study, may also 
confound the applicability of these results beyond 
the present study cohort. In addition, the patients 
enrolled for this study were recruited on the basis 
of systolic HF and were mostly well-compensated 
patients. Therefore, as such, it was perhaps not sur-
prising that the results for patients with IHD and DCM 
were similar, despite the differing original myocardial 
insult. No patients with HF-preserved ejection fraction 
were recruited to this study. Further studies enrolling 
a cohort of patients with HF-preserved ejection frac-
tion would be of benefit to understand whether novel 
4D flow parameters may be of clinical utility in this 
patient population.
This study has highlighted important relationships 
between classical remodeling parameters and novel 
4D flow markers, but, in line with its proof-of-princi-
ple concept, cross-sectional and observational nature, 
it cannot assess the causality of these relationships. In 
addition, the exploratory nature of this study means 
that multiple parameters have been assessed at once 
and therefore mass significance is a potential limitation. 
Although we found with statistical modeling the direct-
flow average KE to be a superior predictor of patients’ 
functional capacity compared with volumetric param-
eters, assessment of the applicability of this result to all 
patients with different causes of HF is beyond the scope 
of this study design.
Clinical Implications
Therapies for HF, including angiotensin-converting 
enzyme inhibitors and β-blockers, have significant-
ly reduced morbidity and mortality.1 However, the 
incidence of HF and burden of disease continues to 
increase, and the need for new therapies remains.2 
Despite numerous phase I and phase II studies describ-
ing potential novel therapies, few of these compounds 
have been successfully translated in clinical trials. The 
reasons for this failure are multifactorial including the 
difficulty of achieving adequate power to demonstrate 
a mortality benefit and the inability to identify effective 
therapies in phase II trials, which may be compounded 
by the use of surrogate end points that are a conse-
quence of remodeling rather than an active part of 
the process.27 Therefore, the identification in this study 
of novel 4D flow imaging biomarkers that may be 
mechanistic in the cardiac remodeling process, rather 
than surrogate markers, warrants further investiga-
tion with longitudinal therapeutic intervention studies, 
potentially providing an early efficacy signal indicat-
ing prognostic benefit more strongly than traditional 
remodeling markers.
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Conclusions
In patients with HF, the direct-flow average KE was the 
only imaging-based independent predictor of func-
tional capacity. 4D flow parameters are novel imaging 
biomarkers that provide additional information about 
disease severity and cardiac remodeling over conven-
tional imaging parameters. We speculate that 4D flow 
parameters may become a powerful surrogate for clini-
cal end points in future HF studies.
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